Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.

Buurman ET, Timofeyeva Y, Gu J, Kim JH, Kodali S, Liu Y, Mininni T, Moghazeh S, Pavliakova D, Singer C, Singh S, Handke LD, Lotvin J, Prasad AK, Scully IL, Donald RGK, Jansen KU, Anderson AS.

J Infect Dis. 2019 Jun 5;220(1):105-115. doi: 10.1093/infdis/jiz062.

2.

Molecular epidemiology and expression of capsular polysaccharides in Staphylococcus aureus clinical isolates in the United States.

Mohamed N, Timofeyeva Y, Jamrozy D, Rojas E, Hao L, Silmon de Monerri NC, Hawkins J, Singh G, Cai B, Liberator P, Sebastian S, Donald RGK, Scully IL, Jones CH, Creech CB, Thomsen I, Parkhill J, Peacock SJ, Jansen KU, Holden MTG, Anderson AS.

PLoS One. 2019 Jan 14;14(1):e0208356. doi: 10.1371/journal.pone.0208356. eCollection 2019.

3.

Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.

McNeil LK, Donald RGK, Gribenko A, French R, Lambert N, Harris SL, Jones TR, Li S, Zlotnick G, Vogel U, Claus H, Abad R, Vazquez JA, Borrow R, Findlow J, Taha MK, Deghmane AE, Caugant DA, Kriz P, Musilek M, Wang X, Vuong J, Mayer LW, Pride MW, Jansen KU, Anderson AS.

MBio. 2018 Mar 13;9(2). pii: e00036-18. doi: 10.1128/mBio.00036-18.

4.

Meningococcal serogroup B vaccines: Estimating breadth of coverage.

Donald RG, Hawkins JC, Hao L, Liberator P, Jones TR, Harris SL, Perez JL, Eiden JJ, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2017 Feb;13(2):255-265. doi: 10.1080/21645515.2017.1264750. Epub 2016 Dec 14. Review.

5.

Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains.

Harris SL, Donald RG, Hawkins JC, Tan C, O'Neill R, McNeil LK, Perez JL, Anderson AS, Jansen KU, Jones TR.

Pediatr Infect Dis J. 2017 Feb;36(2):216-223. doi: 10.1097/INF.0000000000001399.

PMID:
27846061
6.

Elucidation of DnaE as the Antibacterial Target of the Natural Product, Nargenicin.

Painter RE, Adam GC, Arocho M, DiNunzio E, Donald RG, Dorso K, Genilloud O, Gill C, Goetz M, Hairston NN, Murgolo N, Nare B, Olsen DB, Powles M, Racine F, Su J, Vicente F, Wisniewski D, Xiao L, Hammond M, Young K.

Chem Biol. 2015 Oct 22;22(10):1362-73. doi: 10.1016/j.chembiol.2015.08.015. Epub 2015 Oct 8.

7.

A Vaccine Approach for the Prevention of Infections by Multidrug-resistant Enterococcus faecium.

Kodali S, Vinogradov E, Lin F, Khoury N, Hao L, Pavliak V, Jones CH, Laverde D, Huebner J, Jansen KU, Anderson AS, Donald RG.

J Biol Chem. 2015 Aug 7;290(32):19512-26. doi: 10.1074/jbc.M115.655852. Epub 2015 Jun 24.

8.

Isolation, structure elucidation and antibacterial activity of a new tetramic acid, ascosetin.

Ondeyka JG, Smith SK, Zink DL, Vicente F, Basilio A, Bills GF, Polishook JD, Garlisi C, Mcguinness D, Smith E, Qiu H, Gill CJ, Donald RG, Phillips JW, Goetz MA, Singh SB.

J Antibiot (Tokyo). 2014 Jul;67(7):527-31. doi: 10.1038/ja.2014.33. Epub 2014 Apr 2.

PMID:
24690911
9.

Isolation, structure elucidation, and biological activity of altersolanol P using Staphylococcus aureus fitness test based genome-wide screening.

Ondeyka J, Buevich AV, Williamson RT, Zink DL, Polishook JD, Occi J, Vicente F, Basilio A, Bills GF, Donald RG, Phillips JW, Goetz MA, Singh SB.

J Nat Prod. 2014 Mar 28;77(3):497-502. doi: 10.1021/np400759f. Epub 2014 Jan 15.

PMID:
24428261
10.

A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.

Donald RG, Flint M, Kalyan N, Johnson E, Witko SE, Kotash C, Zhao P, Megati S, Yurgelonis I, Lee PK, Matsuka YV, Severina E, Deatly A, Sidhu M, Jansen KU, Minton NP, Anderson AS.

Microbiology. 2013 Jul;159(Pt 7):1254-66. doi: 10.1099/mic.0.066712-0. Epub 2013 Apr 29.

11.

Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.

Singh SB, Goetz MA, Smith SK, Zink DL, Polishook J, Onishi R, Salowe S, Wiltsie J, Allocco J, Sigmund J, Dorso K, de la Cruz M, Martín J, Vicente F, Genilloud O, Donald RG, Phillips JW.

Bioorg Med Chem Lett. 2012 Dec 1;22(23):7127-30. doi: 10.1016/j.bmcl.2012.09.071. Epub 2012 Oct 2.

PMID:
23084277
12.

Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors.

Anderson AS, Miller AA, Donald RG, Scully IL, Nanra JS, Cooper D, Jansen KU.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1585-94. doi: 10.4161/hv.21872. Epub 2012 Aug 24. Review.

13.

A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure.

Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, Vernachio JH, Severina E, Girgenti D, Jansen KU, Anderson AS, Donald RG.

Clin Vaccine Immunol. 2012 Oct;19(10):1641-50. Epub 2012 Aug 15.

14.

Broadening the spectrum of β-lactam antibiotics through inhibition of signal peptidase type I.

Therien AG, Huber JL, Wilson KE, Beaulieu P, Caron A, Claveau D, Deschamps K, Donald RG, Galgoci AM, Gallant M, Gu X, Kevin NJ, Lafleur J, Leavitt PS, Lebeau-Jacob C, Lee SS, Lin MM, Michels AA, Ogawa AM, Painter RE, Parish CA, Park YW, Benton-Perdomo L, Petcu M, Phillips JW, Powles MA, Skorey KI, Tam J, Tan CM, Young K, Wong S, Waddell ST, Miesel L.

Antimicrob Agents Chemother. 2012 Sep;56(9):4662-70. doi: 10.1128/AAC.00726-12. Epub 2012 Jun 18.

15.

Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus.

Phillips JW, Goetz MA, Smith SK, Zink DL, Polishook J, Onishi R, Salowe S, Wiltsie J, Allocco J, Sigmund J, Dorso K, Lee S, Skwish S, de la Cruz M, Martín J, Vicente F, Genilloud O, Lu J, Painter RE, Young K, Overbye K, Donald RG, Singh SB.

Chem Biol. 2011 Aug 26;18(8):955-65. doi: 10.1016/j.chembiol.2011.06.011.

16.

Coelomycin, a highly substituted 2,6-dioxo-pyrazine fungal metabolite antibacterial agent discovered by Staphylococcus aureus fitness test profiling.

Goetz MA, Zhang C, Zink DL, Arocho M, Vicente F, Bills GF, Polishook J, Dorso K, Onishi R, Gill C, Hickey E, Lee S, Ball R, Skwish S, Donald RG, Phillips JW, Singh SB.

J Antibiot (Tokyo). 2010 Aug;63(8):512-8. doi: 10.1038/ja.2010.86. Epub 2010 Jul 28.

PMID:
20664605
17.

Mammalian casein kinase 1alpha and its leishmanial ortholog regulate stability of IFNAR1 and type I interferon signaling.

Liu J, Carvalho LP, Bhattacharya S, Carbone CJ, Kumar KG, Leu NA, Yau PM, Donald RG, Weiss MJ, Baker DP, McLaughlin KJ, Scott P, Fuchs SY.

Mol Cell Biol. 2009 Dec;29(24):6401-12. doi: 10.1128/MCB.00478-09. Epub 2009 Oct 5.

18.

Chemical genetic identification of peptidoglycan inhibitors potentiating carbapenem activity against methicillin-resistant Staphylococcus aureus.

Huber J, Donald RG, Lee SH, Jarantow LW, Salvatore MJ, Meng X, Painter R, Onishi RH, Occi J, Dorso K, Young K, Park YW, Skwish S, Szymonifka MJ, Waddell TS, Miesel L, Phillips JW, Roemer T.

Chem Biol. 2009 Aug 28;16(8):837-48. doi: 10.1016/j.chembiol.2009.05.012.

19.

A Staphylococcus aureus fitness test platform for mechanism-based profiling of antibacterial compounds.

Donald RG, Skwish S, Forsyth RA, Anderson JW, Zhong T, Burns C, Lee S, Meng X, LoCastro L, Jarantow LW, Martin J, Lee SH, Taylor I, Robbins D, Malone C, Wang L, Zamudio CS, Youngman PJ, Phillips JW.

Chem Biol. 2009 Aug 28;16(8):826-36. doi: 10.1016/j.chembiol.2009.07.004.

20.

Changes in the expression of human cell division autoantigen-1 influence Toxoplasma gondii growth and development.

Radke JR, Donald RG, Eibs A, Jerome ME, Behnke MS, Liberator P, White MW.

PLoS Pathog. 2006 Oct;2(10):e105.

21.

Anticoccidial kinase inhibitors: identification of protein kinase targets secondary to cGMP-dependent protein kinase.

Donald RG, Zhong T, Wiersma H, Nare B, Yao D, Lee A, Allocco J, Liberator PA.

Mol Biochem Parasitol. 2006 Sep;149(1):86-98. Epub 2006 May 23.

PMID:
16765465
22.

Characterization of Plasmodium falciparum cGMP-dependent protein kinase (PfPKG): antiparasitic activity of a PKG inhibitor.

Diaz CA, Allocco J, Powles MA, Yeung L, Donald RG, Anderson JW, Liberator PA.

Mol Biochem Parasitol. 2006 Mar;146(1):78-88. Epub 2005 Nov 17.

PMID:
16325279
23.

Differential localization of alternatively spliced hypoxanthine-xanthine-guanine phosphoribosyltransferase isoforms in Toxoplasma gondii.

Chaudhary K, Donald RG, Nishi M, Carter D, Ullman B, Roos DS.

J Biol Chem. 2005 Jun 10;280(23):22053-9. Epub 2005 Apr 6.

24.

Characterization of two T. gondii CK1 isoforms.

Donald RG, Zhong T, Meijer L, Liberator PA.

Mol Biochem Parasitol. 2005 May;141(1):15-27.

PMID:
15811523
25.

Purine salvage pathways in the apicomplexan parasite Toxoplasma gondii.

Chaudhary K, Darling JA, Fohl LM, Sullivan WJ Jr, Donald RG, Pfefferkorn ER, Ullman B, Roos DS.

J Biol Chem. 2004 Jul 23;279(30):31221-7. Epub 2004 May 11.

26.

A role for coccidian cGMP-dependent protein kinase in motility and invasion.

Wiersma HI, Galuska SE, Tomley FM, Sibley LD, Liberator PA, Donald RG.

Int J Parasitol. 2004 Mar 9;34(3):369-80.

PMID:
15003497
27.

Toxoplasma gondii cyclic GMP-dependent kinase: chemotherapeutic targeting of an essential parasite protein kinase.

Donald RG, Allocco J, Singh SB, Nare B, Salowe SP, Wiltsie J, Liberator PA.

Eukaryot Cell. 2002 Jun;1(3):317-28.

28.

Identification and characterization of differentiation mutants in the protozoan parasite Toxoplasma gondii.

Matrajt M, Donald RG, Singh U, Roos DS.

Mol Microbiol. 2002 May;44(3):735-47.

29.

The role of a parasite-specific allosteric site in the distinctive activation behavior of Eimeria tenella cGMP-dependent protein kinase.

Salowe SP, Wiltsie J, Liberator PA, Donald RG.

Biochemistry. 2002 Apr 2;41(13):4385-91.

PMID:
11914085
30.

Molecular characterization of a coccidian parasite cGMP dependent protein kinase.

Donald RG, Liberator PA.

Mol Biochem Parasitol. 2002 Apr 9;120(2):165-75.

PMID:
11897122
31.

Mining the Plasmodium genome database to define organellar function: what does the apicoplast do?

Roos DS, Crawford MJ, Donald RG, Fraunholz M, Harb OS, He CY, Kissinger JC, Shaw MK, Striepen B.

Philos Trans R Soc Lond B Biol Sci. 2002 Jan 29;357(1417):35-46.

32.

Purification and molecular characterization of cGMP-dependent protein kinase from Apicomplexan parasites. A novel chemotherapeutic target.

Gurnett AM, Liberator PA, Dulski PM, Salowe SP, Donald RG, Anderson JW, Wiltsie J, Diaz CA, Harris G, Chang B, Darkin-Rattray SJ, Nare B, Crumley T, Blum PS, Misura AS, Tamas T, Sardana MK, Yuan J, Biftu T, Schmatz DM.

J Biol Chem. 2002 May 3;277(18):15913-22. Epub 2002 Feb 7.

33.
34.

Transport and trafficking: Toxoplasma as a model for Plasmodium.

Roos DS, Crawford MJ, Donald RG, Fohl LM, Hager KM, Kissinger JC, Reynolds MG, Striepen B, Sullivan WJ Jr.

Novartis Found Symp. 1999;226:176-95; discussion 195-8. Review.

PMID:
10645546
35.

The adenosine transporter of Toxoplasma gondii. Identification by insertional mutagenesis, cloning, and recombinant expression.

Chiang CW, Carter N, Sullivan WJ Jr, Donald RG, Roos DS, Naguib FN, el Kouni MH, Ullman B, Wilson CM.

J Biol Chem. 1999 Dec 3;274(49):35255-61.

36.

Insertional tagging of at least two loci associated with resistance to adenine arabinoside in Toxoplasma gondii, and cloning of the adenosine kinase locus.

Sullivan WJ Jr, Chiang CW, Wilson CM, Naguib FN, el Kouni MH, Donald RG, Roos DS.

Mol Biochem Parasitol. 1999 Sep 20;103(1):1-14.

PMID:
10514076
37.

Origin, targeting, and function of the apicomplexan plastid.

Roos DS, Crawford MJ, Donald RG, Kissinger JC, Klimczak LJ, Striepen B.

Curr Opin Microbiol. 1999 Aug;2(4):426-32. Review.

PMID:
10458993
38.

Shikimate pathway in apicomplexan parasites.

Keeling PJ, Palmer JD, Donald RG, Roos DS, Waller RF, McFadden GI.

Nature. 1999 Jan 21;397(6716):219-20. No abstract available.

PMID:
9930696
39.

Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum.

Waller RF, Keeling PJ, Donald RG, Striepen B, Handman E, Lang-Unnasch N, Cowman AF, Besra GS, Roos DS, McFadden GI.

Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12352-7.

40.
41.

Tagging genes and trapping promoters in Toxoplasma gondii by insertional mutagenesis.

Roos DS, Sullivan WJ, Striepen B, Bohne W, Donald RG.

Methods. 1997 Oct;13(2):112-22.

PMID:
9405195
42.

Expression, purification, and characterization of uracil phosphoribosyltransferase from Toxoplasma gondii.

Carter D, Donald RG, Roos D, Ullman B.

Mol Biochem Parasitol. 1997 Aug;87(2):137-44.

PMID:
9247925
43.
45.

Heterologous expression and characterization of the bifunctional dihydrofolate reductase-thymidylate synthase enzyme of Toxoplasma gondii.

Trujillo M, Donald RG, Roos DS, Greene PJ, Santi DV.

Biochemistry. 1996 May 21;35(20):6366-74.

PMID:
8639582
46.

RNA-binding activities of barley stripe mosaic virus gamma b fusion proteins.

Donald RG, Jackson AO.

J Gen Virol. 1996 May;77 ( Pt 5):879-88.

PMID:
8609484
48.

Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics.

Beckers CJ, Roos DS, Donald RG, Luft BJ, Schwab JC, Cao Y, Joiner KA.

J Clin Invest. 1995 Jan;95(1):367-76.

50.

Supplemental Content

Loading ...
Support Center